Merck Buys Sirna Therapeutics
Merck & Co. said Monday that it is acquiring San Francisco-based Sirna Therapeutics, in a transaction worth $1.1B. Sirna Therapeutics develops medicines based on RNA interference (RNAi) technology. Merck will acquire 100 percent of the equity of Sirna for $13 per share in cash. Sirna's RNAi therapeutics are aimed at treating cancer and other conditions. The firm was backed by Oxford Bioscience Partners, Sprout Group, Venrock Associates, and others. Sirna's manufacturing operations are based in Boulder, Colorado.
posted on Tuesday, October 31, 2006
Related companies:
Merck
Related stories:
> Dharmacon, Abbott Collaborate on siRNA Therapeutics
> miRagen Therapeutics Gets $41M
> miRagen Therapeutics Raises $40M, Goes Public In Reverse Merger
> Remedy Informatics Snags Funding From Merck
> Insys Therapeutics Files For IPO
Techrockies.com Home